180 related articles for article (PubMed ID: 29167217)
21. Safe administration of S-1 after 5-fluorouracil-induced cardiotoxicity in a patient with colorectal cancer.
Franck C; Malfertheiner P; Venerito M
BMJ Case Rep; 2017 May; 2017():. PubMed ID: 28536214
[TBL] [Abstract][Full Text] [Related]
22. Oral status in patients receiving 5-fluorouracil for colorectal cancer.
Djuric M; Cakic S; Hadzi-Mihailovic M; Petrovic D; Jankovic L
J BUON; 2010; 15(3):475-9. PubMed ID: 20941813
[TBL] [Abstract][Full Text] [Related]
23. Diffusion-weighted magnetic resonance imaging in early stage of 5-fluorouracil-induced leukoencephalopathy.
Tha KK; Terae S; Sugiura M; Nishioka T; Oka M; Kudoh K; Kaneko K; Miyasaka K
Acta Neurol Scand; 2002 Dec; 106(6):379-86. PubMed ID: 12460146
[TBL] [Abstract][Full Text] [Related]
24. [5-Fluorouracil-induced small bowel toxicity in a patient with colorectal cancer].
Llorca Ferrándiz C; Esquerdo Galiana G; Cervera Grau JM; Briceño García HC; Calduch Broseta JV; Del Pino Cuadrado J
Clin Transl Oncol; 2005 Sep; 7(8):356-7. PubMed ID: 16185605
[TBL] [Abstract][Full Text] [Related]
25. A case of acute myocardial infarction during 5-fluorouracil infusion.
Canale ML; Camerini A; Stroppa S; Porta RP; Caravelli P; Mariani M; Balbarini A; Ricci S
J Cardiovasc Med (Hagerstown); 2006 Nov; 7(11):835-7. PubMed ID: 17060812
[TBL] [Abstract][Full Text] [Related]
26. Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity.
Deboever G; Hiltrop N; Cool M; Lambrecht G
Clin Colorectal Cancer; 2013 Mar; 12(1):8-14. PubMed ID: 23102544
[TBL] [Abstract][Full Text] [Related]
27. [Reversible cardiogenic shock under 5-fluorouracil treatment].
Bakouboula B; Morel O; Douchet MP; Chauvin M
Ann Cardiol Angeiol (Paris); 2005 Aug; 54(4):216-9. PubMed ID: 16104623
[TBL] [Abstract][Full Text] [Related]
28. A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer.
Chen ML; Fang CH; Liang LS; Dai LH; Wang XK
Surg Oncol; 2010 Mar; 19(1):38-45. PubMed ID: 19345093
[TBL] [Abstract][Full Text] [Related]
29. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage.
Gamelin E; Boisdron-Celle M; Guérin-Meyer V; Delva R; Lortholary A; Genevieve F; Larra F; Ifrah N; Robert J
J Clin Oncol; 1999 Apr; 17(4):1105. PubMed ID: 10561167
[TBL] [Abstract][Full Text] [Related]
30. [A case of acute leukoencephalopathy induced by a combination of 5-fluorouracil and metronidazole].
Fukumoto T; Katada F; Sato S; Shibayama H; Murayama S; Fukutake T
Rinsho Shinkeigaku; 2018 Feb; 58(2):118-123. PubMed ID: 29386497
[TBL] [Abstract][Full Text] [Related]
31. Lethal leukoencephalopathy secondary to Tegafur, a 5-fluorouracil prodrug.
Sierra S; Luquin N; Carrato C
J Neurol Sci; 2015 Oct; 357(1-2):326-8. PubMed ID: 26242718
[No Abstract] [Full Text] [Related]
32. DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer.
Nahid NA; Apu MNH; Islam MR; Shabnaz S; Chowdhury SM; Ahmed MU; Nahar Z; Islam MS; Islam MS; Hasnat A
Cancer Chemother Pharmacol; 2018 Jan; 81(1):119-129. PubMed ID: 29134491
[TBL] [Abstract][Full Text] [Related]
33. Second-line treatment with high-dose 5-fluorouracil and folinic acid in advanced colorectal cancer refractory to standard-dose 5-fluorouracil treatment.
Jäger E; Klein O; Wächter B; Müller B; Braun U; Knuth A
Oncology; 1995; 52(6):470-3. PubMed ID: 7478433
[TBL] [Abstract][Full Text] [Related]
34. Capecitabine Versus Continuous Infusion Fluorouracil for the Treatment of Advanced or Metastatic Colorectal Cancer: a Meta-analysis.
Wu Z; Deng Y
Curr Treat Options Oncol; 2018 Nov; 19(12):77. PubMed ID: 30483908
[TBL] [Abstract][Full Text] [Related]
35. The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients.
Zhou ZW; Wang GQ; Wan de S; Lu ZH; Chen YB; Li S; Chen G; Pan ZZ
Chemotherapy; 2007; 53(2):127-31. PubMed ID: 17308379
[TBL] [Abstract][Full Text] [Related]
36. Lactose intolerance associated with adjuvant 5-fluorouracil-based chemotherapy for colorectal cancer.
Osterlund P; Ruotsalainen T; Peuhkuri K; Korpela R; Ollus A; Ikonen M; Joensuu H; Elomaa I
Clin Gastroenterol Hepatol; 2004 Aug; 2(8):696-703. PubMed ID: 15290663
[TBL] [Abstract][Full Text] [Related]
37. Chemotherapy induced stroke mimic: 5-Fluorouracil encephalopathy fulfilling criteria for tissue plasminogen activator therapy.
Nguyen MT; Stoianovici R; Brunetti L
Am J Emerg Med; 2017 Sep; 35(9):1389-1390. PubMed ID: 28711275
[TBL] [Abstract][Full Text] [Related]
38. Lethal toxicity after 5-fluorouracil chemotherapy and its possible relationship to dihydropyrimidine dehydrogenase deficiency: a case report and review of the literature.
Díaz R; Segura A; Aparicio J; Calderero V; Guerrero A; Pellín L
J Chemother; 2004 Dec; 16(6):599-603. PubMed ID: 15700854
[TBL] [Abstract][Full Text] [Related]
39. Bolus injection (2-4 min) versus short-term (10-20 min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomised trial. Nordic Gastrointestinal Tumour Adjuvant Therapy Group.
Glimelius B; Jakobsen A; Graf W; Berglund A; Gadeberg C; Hansen P; Kjaer M; Brunsgaard N; Sandberg E; Lindberg B; Sellström H; Lorentz T; Påhlman L; Gustavsson B
Eur J Cancer; 1998 Apr; 34(5):674-8. PubMed ID: 9713273
[TBL] [Abstract][Full Text] [Related]
40. Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients.
Teh LK; Hamzah S; Hashim H; Bannur Z; Zakaria ZA; Hasbullani Z; Shia JK; Fijeraid H; Md Nor A; Zailani M; Ramasamy P; Ngow H; Sood S; Salleh MZ
Ther Drug Monit; 2013 Oct; 35(5):624-30. PubMed ID: 23942539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
